Sorafenib (Nexavar®, Bayer HealthCare Pharmaceuticals) is a small molecule that inhibits tumor-cell proliferation and tumor angiogenesis by inhibiting the serine–threonine kinases BRAF and the receptor tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3 as well as the platelet-derived growth factor receptor β (PDGFR-β) [22]. This evidence concerns the gene NTRK1 and neoplasm.